By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


ArQule, Inc. 

19 Presidential Way

Woburn  Massachusetts  01801  U.S.A.
Phone: 781-994-0300 Fax: 781-376-6019



Drug Discovery




Daiichi Sankyo, Inc. 

Company News
ArQule, Inc. (ARQL) And National Human Genome Research Institute Of NIH Announce Enrollment Of First Patient In The Phase 1 Proteus Syndrome Trial With ARQ 092 11/17/2015 11:26:03 AM
ArQule, Inc. (ARQL) Presents Data On Tivantinib And Propietary Pipeline At AACR-NCI-EORTC Conference 11/9/2015 11:41:07 AM
ArQule, Inc. (ARQL) To Present Data On Tivantinib, ARQ 087, ARQ 092, And ARQ 751 At AACR-NCI-EORTC Conference 10/27/2015 12:47:02 PM
ArQule, Inc. (ARQL) Announces Publication Of Manuscript Highlighting Activity Of AKT Inhibitor ARQ 092 And Next Generation AKT Inhibitor ARQ 751 In Oncology 10/15/2015 2:21:37 PM
ArQule, Inc. (ARQL) Presents Results From Phase 1b Expansion Study Of ARQ 092 At The 2015 European Cancer Conference 9/28/2015 4:00:24 PM
ArQule, Inc. (ARQL) To Present At Leerink Partners 4th Annual Rare Disease Roundtable On September 30, 2015 9/25/2015 9:03:30 AM
ArQule, Inc. (ARQL) To Report Second Quarter 2015 Financial Results On August 5, 2015 7/29/2015 10:52:41 AM
ArQule, Inc. (ARQL) Announces Interim Phase II Study Results For Tivantinib In Combination With Cetuximab In Patients With MET-High, KRAS Wild Type Colorectal Cancer Presented At ESMO World Congress On Gastrointestinal Cancer 2015 7/6/2015 7:42:31 AM
ArQule, Inc. (ARQL) Appoints Robert J. Weiskopf As Chief Financial Officer 6/1/2015 1:46:37 PM
ASCO15: ArQule, Inc. (ARQL) Announces Data Presentations With Tivantinib And ARQ 087 To Be Featured At ASCO 2015 6/1/2015 1:35:45 PM